SPONSOR
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2, Phase 3
NCT06115902 Phase 1
Recruiting
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Breast Cancer
NCT06767813 Phase 2
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Pancreatic Neoplasms
NCT07003074 Phase 3
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Breast Cancer